New therapies for advanced glycation end product nephrotoxicity: Current challenges

American Journal of Kidney Diseases

Volumn 41, Issue 3 SUPPL. 1, 2003, Pages

  Williams, Mark E ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

Diabetic nephropathy; Glycosylation; Treatment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; PENTOSIDINE; PYRIDOXAMINE;

BASEMENT MEMBRANE; CONFERENCE PAPER; CROSS LINKING; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DRUG EFFECT; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GLYCOSYLATION; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; NEPHROTOXICITY; NONHUMAN;

EID: 0037374652     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2003.50083     Document Type: Conference Paper

References (31)

1. Blumberg BS. Fox RC: The Daedalus effect: Changes in ethical questions relating to hepatitis B virus. Ann Intern Med 102:390-396, 1985
2. Nishikawa T, Edelstein D, Brownlee M: The missing link: A singly unifying mechanism for diabetic complication. Kidney Int Suppl 77:S26-S30, 2000
3. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
4. Horie K: Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 100:2995-2999, 1997
5. Heidland A, Sebekova K, Schinzel R: Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38:S100-S106, 2001 (suppl 1)
6. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: A review. Diabetologia 44:129-146, 2001
7. Deuther-Conrad W, Franke S, Sommer M, Henle T, Stein G: Differences in the modulating potential of advanced glycation end product (AGE) peptides versus AGE proteins. Kidney Int Suppl 78:S63-S66, 2001
8. Berg TJ, Bangstad HJ, Torjesen PA, et al: Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 46:661-665, 1997
9. Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H: The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 49:1030-1035, 2000
10. Sugiyama S, Miyata T, Ueda Y, et al: Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J Am Soc Nephrol 9:1681-1688, 1998
11. Bendayan M: Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int 54:438-447, 1998
12. Mene P, Festuccia F, Polci R, Pugliese F, Cinotti GA: Diabetic nephropathy and advanced glycation end products. Contrib Nephrol 131:22-32, 2001
13. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91:11704-11708, 1994
14. Niwa T, Katsuzaki T, Miyazaki S, et al: Immunohistochemical detection of imidazolone, a novel advanced glycation end product in kidneys and aortas of diabetic patients. J Clin Invest 99:1272-1280, 1997
15. Wautier JL, Guillausseau PJ: Advanced glycation end-products, their receptors, and diabetic angiopathy. Diabetes Metab 27:536-542, 2001
16. Schmidt AM, Hori G, Cao R, et al: RAGE: A novel cellular receptor for advanced glycation end-products. Diabetes 45:S577-S580, 1996 (suppl 3)
17. Raj DSC, Choudhury D, Welboume TC, Levi M: Advanced glycation end-products: A nephrologist's perspective. Am J Kidney Dis 35:365-380, 2000
18. Yamamoto Y, Kato I, Doi T, et al: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261-268, 2001
19. Oldfield MD, Bach LA, Forbes JM, et al: Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 108:1853-1863, 2001
20. Soulis-Liparota T, Cooper M, Papazoglou D: Retardation by aminoguanidine of the development of albuminuria, mesangial expansion, and tissue fluorescence in the streptozotocin-induced rat. Diabetes 40:1328-1335, 1991
21. Youssef S, Nguyen DJ, Soulis T, Panagiotopoulos S, Jerums G, Cooper ME: Effects of diabetes and aminoguanidine therapy in renal advanced glycation end-product binding. Kidney Int 55:907-916, 1999
22. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G: Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 50:627-634, 1996
23. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME: Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 12:2098-2107, 2001
24. Osiaka TM, Yu Y, Lee Y, Panagiotopoulos S, Kemp B, Jerums G: Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina, and mesenteric artery. Clin Sci 100:249-257, 2001
25. Appel G, Bolton K, Freedman B, Wuerth JP. Cartwright K: Pimagedine (PG) lowers total urinary protein (TUP) and slows progression of overt diabetic nephropathy in patients with type 1 diabetes mellitus (DM). J Am Soc Nephrol 10:153A, 1999 (abstr)
26. Booth AA, Khalifa RG, Todd P, Hudson BG: In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 272:5430-5437, 1997
27. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits lipoxidation reactions. J Biol Chem 275:21177-21184, 2000
28. Rahbar S, Yerneni KK, Scott S, Gonzales N, Lalezari I: Novel inhibitors of advanced glycation endproducts (Part II). Mol Cell Biol Res Commun 3:360-366, 2000
29. Baynes JW, Degenhardt TP, Anderson NL, Thorpe SR: Pyridorin, a post-Amadori inhibitor of advanced glycation reactions, preserves renal function in diabetic rats. J Am Soc Nephrol 8:628A, 1997 (abstr)
30. Degenhardt TP, Alderson NL, Arrington DD, et al: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939-950, 2000
31. Wolffenbuttel BH, Boulanger CM, Crijns FR, et al: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 95:4630-4634, 1998